Icon
+91 94997 68112
Login Register

Uptravi - (0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6 mg; Tablet,)

Selexipag Actelion pharmaceuticals
0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6 mg; Tablet,
More Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
UPTRAVI is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
Yes
******* ******** ****** **** ***********, ***** ******* ******** **, **** *** ****, ******, ******* *** ***** ****** *** ****. *** ****, ****** *** ******* ***** **** ** ******* '***, '*** *** **** *********.. ***** ****** ***** * **** ** ** ******* '***, '***, '*** *** *** *********. ** ****** **** **** **** ****** ** *** ****. ***** **** *** **** ** ** ** '***. ***** ** *** **, **** **** ******* ******** *** ******* *** ******* **** *********** *****. * **** **** ***** * **** *** ** ****** '*** *** ***** **** ** *** **** ******. *********, ** ******* ****** ** ** ******** ****** *** **, ****. *** *** ******* ******** ********* ******** ****** ** ****** ** **** ******; **** *** ******** *** *** *** ***********. ** *** ****, ******* ******** ******** ** ***** **** ** ****** **** ****** '***, ** ***** **** *** ********** ***** * **** ***. ******** **** ***** * *** **** ******* *******.
Uptravi Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
*** **** **** *** ****** ******* *** ********* ******* *** ********* (***** ******) *** ********* (***** ******)
******* ******* ******* ***** **** ** ** ***** *** ******* *** ********* (***** ******) *** ********* (***** ******)
***** ****** **** ** ** ******* *** ********* ******* *** ********* (***** ******) *** ********* (***** ******)
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** **** *** \ *** *** *, **** ******* ********* ******** ******* *** **** *** *** ****
******* *** \ *** *** **, **** ********* **** / ******* ********* ******** ******* *** **** *** *** ****
***** ****** *** \ ********* *** *, **** **** ** ** ********* ******** ******* *** **** *** *** ****
  1. *** **, **** : *** **** ******** ******** ***** **'* **** ** ****** ** ******* '*** , '*** *** **** *** ****** ** ****** '***
  2. *** **, **** : ******* ******** ******** ***** **'* **** ** ****** ** ******* '*** , '*** *** **** *** ****** ** ****** '***
  3. *** *, **** : ***** ****** ******** ***** **'* **** ** ****** ** ******* '***, '*** *** '***
  4. *** **, **** : ****** ******** ******** ***** **'* **** ** ****** ** ******* '*** , '*** *** **** *** ****** ** ****** '***
  5. *** *, **** : ******** ***** * **** ******* *** ****, ******* ****** *** ****** ****** ** ******* '*** *** '*** .
  6. *** *, **** : ******** ***** * **** ******* ***** ****** ** ******* '***, '*** *** '***
  7. *** **, **** : ****** ** ****** '*** *** '*** ******* ******** *** ***** ****** **** ********* ******* *********.
  8. *** **, **** : ****** ** ****** '*** *** '*** ******* ********, *** ****, ****** *** ****** ****** **** ********* ******* *********. ** ****** ** *** * **********
  9. *** **, **** : ***** ****** **** *** **** ** **
  10. *** **, **** : **** ******* ******** *** ******* *** ******* **** *********** *****.
  11. *** **, **** : **** ******* ******** *** ******* *** ******* **** *********** *****
  12. *** **, **** : ******* ******** ******** ** ***** **** ** ****** **** ****** '***. ******* *** ********** ***** * **** *** ************* **** '*** *** ***** ********* ** ** * **** **.
  13. *** **, **** : **** ******* ******** *** ******* *** ******* **** *********** *****
  14. *** *, **** : ******** **** ******* **** ************ ** ****** '***
  15. *** *, **** : ******** ******* **** ******* **** ******* ********* ******** *** ************** ** ****** '***.

Uptravi - (1.8 mg/vial ; Powder, Intravenous)

Selexipag ACTELION
1.8 mg/vial ; Powder, Intravenous
More Than $1000 mn
Less Than 5
Less Than 5
None
Less Than 5
None None
UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
Yes
*** (******) ***** * **** ** *** *** ********* ** ******** ** *** ****.
Uptravi Patent 1 Patent 2 Patent 3 Patent 4
******* *** ********* ******* ***** ******** ******** *** ********* ******* ***** ******** ********
***** *** ********* ******* ***** ******** ******** *** ********* ******* ***** ******** ********
***** *** ********* **** ** *** **, **** *** ********* **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ********* *** **, **** ******* **** ******* *** **** *** *** ****
***** ** \ ** *** **, **** ******* ********* ******** ******* *** **** *** *** ****
***** ** \ ** *** **, **** ******* ********* ******** *** ****** *** ****
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** **, **** : ******* ******** ******** ** *** ****-** ****** **** ******* '*** *** '***
  3. *** *, **** : ******** **** ******* **** ************ ** ******* '*** *** '***
  4. *** *, **** : ***** ******** ******** ** *** ****-** ****** **** ******* '*** *** '***
  5. *** *, **** : ******** **** ***** **** ************ ** ******* '*** *** '***
  6. *** **, **** : ***** ******** ******** ** ***** **** ** ******
  7. *** *, **** : ******** **** ***** **** ************ ** ******* '*** *** '***
  8. *** **, **** : *** **** ******** ******** ** ***** **** ** ******.
  9. *** *, **** : ******** **** *** **** **** ************ ** ******* '*** *** '***
  10. *** **, **** : ********* *** ******* ******* ********** **** ************ ** ******* '*** *** '***. ******* ****** ******** *** **************.
  11. *** **, **** : ********* *** ***** ******* ********** **** ************ ** ******* '*** *** '***. ***** ****** ******** *** **************.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.